At United Therapeutics, we find tremendous inspiration for our work and view our products as being new beginnings for patients and doctors, with quality of life as our utmost therapeutic goal. The theme of  United Therapeutics is "Medicines for Life" because all of our therapeutics address life-threatening illnesses.

Much of United Therapeutics' resources are focused on cardiovascular health, including developing analogs of the endogenous hormone prostacyclin  for the treatment of pulmonary arterial hypertension and critical limb ischemia and a variety of telemedicine services for patients with an array of possible cardiac arrhythmias. United Therapeutics's second focus is in the field of infectious disease, where the company is targeting hepatitis C and other diseases with unique glycobiology compounds. While this work is at an early stage, it holds immense promise. The diseases being targeted afflict over a billion people worldwide, and the compounds are part of an entire new class of pharmacological agents.Our third focus is on the treatment of cancer with monoclonal antibodies. We are currently developing treatments to target neuroblastoma and metastatic brain cancer.

We strive for balance within and across our therapeutic areas. Our cardiovascular drug development strategy is balanced with a commercialized use (pulmonary arterial hypertension ),as well as novel uses and new routes of administration. And our overall company strategy is balanced among mature programs, pivotal development, and early-stage pipeline activities.

The company's mission is carried out using corporate partners for product sales and academic centers for research whenever feasible, complemented by in-house commercialization professionals and our commitment to providing doctors and patients with accurate information and ongoing research related to our products. This strategy streamlines company overhead and enables company employees to concentrate on clinical trials, regulatory approvals and business development. United Therapeutics generally retains all rights to the products it develops.

United Therapeutics Corporation is incorporated in Delaware and is listed on the NASDAQ  stock market  under the symbol "UTHR".